In April of 2013, construction of NKY’s new plant with 138,800 m2of land and 50,000 m2of structure was completed, making it the production center for our PVP and PVM/MA polymer families. The new facilities includes production capacity of: 12,000 tons/year GBL; 5,000 tons/year 2-pyrrolidone; 5,000 tons/year NVP; 2,500 tons/year PVM/MA copolymer; 2,000 tons/year MVE and 5,000 tons/year PVP’s.
Our product offerings include: GBL, 2-P, NVP monomer, PVP K series, Copovidone, VP/VA copolymer series, PVPP, PVP-I complex, vinyl ether intermediate and PVM/MA copolymers. NKY is the only domestic company capable of manufacturing PVP K-12 (powder and liquid) and PVP K-60, K-90 and K-120 powders.
All pharmaceutical, cosmetic, food and oral care products are manufactured according to cGMP regulations in our new facilities, making it a model for China’s excipient and food additive’s production safety management.
With the establishment of the R&D Center in Boai and the Technical Research Center in Tianjin, NKY is committed to R&D and the development of new products and technologies to bring new solutions and value to their customers. We are continuously striving to become the most trusted partner to our customers by providing materials that meet their quality requirements and enhance their finished product’s performance.
The company continues to develop new technologies and capabilities to better serve its market as can be attested by the many company patents and distinctions. Recently, NKY has been awarded the distinction as National Torch Plan high-tech company, qualifying the company as a State-level high-tech enterprise. On a provincial level, our technical R&D center has been qualified as a Jiaozuo innovation center and our company as an environmentally responsible enterprise.
We provide high
quality pharmaceutical excipients for our customers in more than 60 countries worldwide.
Boai
NKY has formally registered on REACH for PVP/Monomer NVP (upto 1000MT/a),
Register No.: 01-2119498301-39-0002
NKY®is the registered trademark of Boai NKY Pharmaceuticals Ltd (NKY). KoVidone®, PolyKoVidone®, PolyFilter®, PolyViscol®, WhiVidone®, OraRez®are the trademark names of NKY.
-
KoVidone® as binder, solubilizer, dispersant & coating agent; PolyKoVidone® as super disintegrant.
-
NKY® PVP series for water treatment, glue sticks, inks, membrane, textile, oil recovery, glass fiber etc.
-
OraRez® series for denture adhesive, mouthwash, toothpaste.
-
PolyViscol® series for hair-styling & skin care as film-former, thinkening agent.
-
PolyFilter® as stabilizer for beer, wine and beverages.
-
NKY® N-Vinyl Pyrrolidone(NVP), 2-Pyrrolidone(2-P), and Vinyl Ethers.
Customer first: quality first, continuous innovation, the pursuit of excellence.
Business purpose: research and development of functional polymer new products, leading human life.
Business philosophy: quality management is the program of our management, technical innovation is the fundamental to our survival, customer satisfaction is the yardstick to measure our
work, the creation of brand name is our goal.
- 2018-03-01Notification of the renaming of Boai NKY Pharmaceuticals Ltd. Read more<<
-
2017-12-01Congratulations: "strategic cooperation framework agreement“ signed between People's Government of Songjiang District of Shanghai and Boai NKY!
On November 28th afternoon, songjiang Shanghai hujia hangzhou G60 will be held kechuang corridor (Shanghai songjiang) with melting propulsion conference, promote industrial and financial depth fusion, booster G60 will be hujia hangzhou kechuang corridor construction, building with melting new heights.Boai Nky Pharmaceuticals Ltd. (hereinafter referred to as the "love the new open source" or the "company"), general manager Mr Wang Donghu jun-zheng zhang, deputy general manager Mr And lattice general manager Mr Zou Xiaowen to attend this conference.The meeting, represented by general manager Mr Wang Donghu, love the new open source through friendly consultation with Shanghai's songjiang district people's government signed a strategic cooperation framework agreement, the signing of the agreement to facilitate integration and play both sides in such aspects as culture, location, industry, channel resources and advantages. Songjiang has a long history, cultural prosperity, cultural gathering and convenient transportation. It is a modern new city built by Shanghai and is an important urban area of the Yangtze river delta.Songjiang district as the center of the Shanghai construction global influence kechuang important bearing area, the real economy and advanced manufacturing new heights, with the G60 will be kechuang corridor for the gripper, focus on artificial intelligence, intelligent security, new energy, new materials, biological medicine, energy conservation, environmental protection and other strategic emerging industries, "6 + X" kechuang drive "songjiang manufacturing" to "create" songjiang.The future songjiang district will attract more and more attention from Chinese and foreign enterprises as the focus and influence of the G60 science and innovation corridor are continuously improved.New open source is the first in China to research, develop and produce PVP products.Through nearly 30 years of forge ahead, in improving production technology and automatic control level, improve the industrial structure, expand the scale of production, improve the level of quality management and other aspects have made great progress.In the global PVP industry, China ranks first and third in the world.The "framework agreement" signed, love the new open source transformation of global research and development base for the subsequent main business will be born songjiang, strategic emerging industry cluster to promote the G60 will be kechuang corridor layout to make positive contribution.New open source at the same time, love will be in Shanghai songjiang investment research construction, laboratory and industrial base and setting up industry investment funds, the company will actively participate in the construction and development of songjiang district, for the further upgrading, development of songjiang advantage industry make a positive contribution.
Read more<< -
2017-11-15NKY and Heidelberg University Medical School signed the Letter of Intent for the cooperation in the new generation early breast cancer in-vitro molecular screening technology
On November 11, 2017, the autumn color of Beijing is strong, and the red leaves of the fragrant hills are attractive.NKY PRECISION MEDICINE and the thousands of thousands of German guests gathered at the foot of xiangshan, the first step in a new open source collaboration with Heidelberg university medical school.Germany Heidelberg university school of medicine, has 600 years of history, contributed a number of Nobel Prize winner, is recognized as the world's top medical office, the world's unique heavy ion and proton therapy center is located in the campus.Is the representative of visiting Germany, Heidelberg university women's hospital dean Christof Sohn, professor and Heidelberg university school of medicine, "a new generation MammaScreen early breast cancer in vitro molecular screening technology group leader Dr Sarah Schott."MammaScreen a new generation of early breast cancer in vitro molecular screening technology" and the German national cancer research center jointly by the university of Heidelberg project, a multi-year research and development, through the detection of specific molecular markers in peripheral blood women, very early accurate diagnosis of breast cancer, can make up for the existing various types of breast cancer screening technology.As well as further screening for breast cancer, MammaScreen researchers have begun to explore the use of ovarian and pancreatic cancer and have made preliminary results.The NKY invited to Sohn to visit Beijing and Schott, Ph.D., professor, as specially invited guests attended the "second session of Beijing precision medical treatment of breast cancer and translational medicine BBS" and MammaScreen technology do academic report, signed a cooperation intentions.At the scene of the signing ceremony, the new open source also invited to Beijing maternity and child health care hospital director of oncology wing-keung cheung, haidian Ma Xiangjun, vice President of the six domestic well-known experts, with the German experts MammaScreen technology principle and clinical trials in China has made the detailed communication, MammaScreen won the experts unanimously spoke highly of China.NKY vice chairman wang jianqiang and professor Sohn respectively signed the letter of intent for the project."NKY is our best partner in China. Today is the beginning of great cooperation between us, and it is the beginning of a great friendship," said professor Sohn, who was pleased to sign the contract.wang jian qiang, vice chairman of the board of directors has expressed the group completes the determination and confidence in the project, "our NKY has always attached great importance to technical and scientific research, cooperation with the world's top medical school this time, is both an opportunity and challenge for us, in the next clinical trial and marketing, we must achieve excellence and absorption of Germany advanced technology and experience, at the same time listen to domestic experts valuable guidance, to make a benefit of Chinese women's breast cancer detection product."Signing ceremony held at the foot of xiangshan in the day of the second session of Beijing precision medical treatment of breast cancer and translational medicine BBS ", is an annual event, the national breast cancer field sponsored new open source has two years in a row.Hundreds of experts, including academician jin Ming, have come from all over the country to share an academic feast of breast cancer diagnosis and treatment.Dr Sohn and Dr Schott introduced MammaScreen technology in detail at the conference, laying a solid foundation for the future academic promotion of new open source.NKY PRECISION MEDICINE's cooperation with Heidelberg university medical school will surely achieve fruitful results.
Read more<<
